GlassScriptPhysician profile
Richard N Sherman
NPI 1700889177
$4,139.81
in general payments reported to CMS, 2019-2025
24 companies · $700 in 2025
The $700 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $233 · 2021: $428 · 2022: $541 · 2023: $1,422 · 2024: $418 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,460.19 | 2019-2025 | Epsolay, Dysport, Oracea |
| Hill Dermaceuticals, INC. | $779.52 | 2023-2025 | Tolak |
| Incyte Corporation | $293.46 | 2022-2025 | Opzelura |
| Amgen INC. | $204.00 | 2020-2024 | Otezla |
| Almirall LLC | $181.77 | 2019-2025 | Seysara, Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $180.10 | 2019-2024 | Arazlo, Jublia, Duobrii |
| Revance Therapeutics, INC. | $159.35 | 2025 | Daxxify |
| Pfizer INC. | $154.69 | 2019-2023 | |
| Journey Medical Corporation | $120.81 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $88.11 | 2022-2023 | Apexicon E |
| Dermavant Sciences, INC. | $72.49 | 2023-2024 | Vtama |
| Organon LLC | $71.02 | 2025 | Vtama |
| Janssen Biotech, INC. | $62.10 | 2025 | Tremfya |
| Cipher Pharmaceuticals US LLC | $56.73 | 2025 | Spinosad, Natroba |
| Sun Pharmaceutical Industries INC. | $51.75 | 2019-2023 | Absorica Ld, Winlevi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $37.53 | 2024-2025 | Clindacin Etz |
| Mayne Pharma Commercial LLC | $31.80 | 2021-2025 | |
| Abbvie INC. | $25.30 | 2024 | |
| Dermira, INC. | $22.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.71 | 2023 | Sotyktu |
| Allergan, INC. | $19.13 | 2021 | |
| Aclaris Therapeutics, INC. | $18.21 | 2019 | |
| Merck Sharp & Dohme LLC | $15.22 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.64 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.